Prognostic value of DNMT3A mutations in myelodysplastic syndromes: a meta-analysis

References

• Greenberg PL, Attar E, Battiwalla M, et al. Myelodysplastic syndromes. J Natl Compr Canc Netw. 2008;6(9):902–926.
   PubMedGoogle Scholar
• Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–3627. doi:10.1182/blood-2013-08-518886.
   PubMed Web of Science ®Google Scholar
• Xu Y, Li Y, Xu Q, et al. Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing. Oncotarget. 2017;8(47):82475–82490. doi:10.18632/oncotarget.19628.
   PubMedGoogle Scholar
• Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219–220. doi:10.1038/890.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–428. doi:10.1038/nrg816.
   PubMed Web of Science ®Google Scholar
• Simpson DJ, Hibberts NA, McNicol AM, et al. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res. 2000;60(5):1211–1216.
   PubMed Web of Science ®Google Scholar
• Auclair G, Guibert S, Bender A, et al. Ontogeny of CpG island methylation and specificity of DNMT3 methyltransferases during embryonic development in the mouse. Genome Biol. 2014;15(12):545, doi:10.1186/s13059-014-0545-5.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683–692. doi:10.1016/j.cell.2007.01.029.
   PubMed Web of Science ®Google Scholar
• Khan H, Vale C, Bhagat T, et al. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol. 2013;50(1):16–37. doi:10.1053/j.seminhematol.2013.01.001.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood. 2009;113(6):1315–1325. doi:10.1182/blood-2008-06-163246.
   PubMed Web of Science ®Google Scholar
• Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241–247. doi:10.1038/leu.2013.336.
   PubMed Web of Science ®Google Scholar
• Ghannam D E, Taalab MM, Ghazy HF, et al. DNMT3A r882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndrome. Blood Cells Mol Dis. 2014;53(1-2):61–66. doi:10.1016/j.bcmd.2014.01.004.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433. doi:10.1056/NEJMoa1005143.
   PubMed Web of Science ®Google Scholar
• Yuan XQ, Peng L, Zeng WJ, et al. DNMT3A r882 mutations predict a poor prognosis in AML: a meta-analysis from 4474 patients. Medicine (Baltimore). 2016;95(18):e3519. doi:10.1097/MD.0000000000003519.
   PubMed Web of Science ®Google Scholar
• Thol F, Winschel C, Lüdeking A, et al. Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica. 2011;96(12):1870–1873. doi:10.3324/haematol.2011.045559.
   PubMed Web of Science ®Google Scholar
• Brecqueville M, Cervera N, Gelsi-Boyer V, et al. Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes. Blood Cancer J. 2011;1(5):e18. doi:10.1038/bcj.2011.15.
   PubMed Web of Science ®Google Scholar
• Lin ME, Hou HA, Tsai CH, et al. Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clin Epigenetics. 2018;10:42. doi:10.1186/s13148-018-0476-1.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia. 2011;25(7):1153–1158. doi:10.1038/leu.2011.44.
   PubMed Web of Science ®Google Scholar
• Xu F, Wu LY, He Q, et al. Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Sci Rep. 2017;7:43113, doi:10.1038/srep43113.
   PubMed Web of Science ®Google Scholar
• Martín I, Such E, Navarro B, et al. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). Leuk Lymphoma. 2017;58(7):1686–1693. doi:10.1080/10428194.2016.1246725.
   PubMed Web of Science ®Google Scholar
• Jung SH, Kim YJ, Yim SH, et al. Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. Oncotarget. 2016;7(34):55264–55275. doi:10.18632/oncotarget.10526.
   PubMedGoogle Scholar
• Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014;32(25):2691–2698. doi:10.1200/JCO.2013.52.3381.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Zhou JD, Yang DQ, et al. Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome. Clin Chem Lab Med. 2018;56(3):485–491. doi:10.1515/cclm-2016-0142.
   PubMed Web of Science ®Google Scholar
• Lin CC, Hou HA, Chou WC, et al. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol. 2014;89(2):137–144. doi:10.1002/ajh.23596.
   PubMed Web of Science ®Google Scholar
• Gangat N, Mudireddy M. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model. Am J Hematol. 2018;93(5):691–697. doi:10.1002/ajh.25064.
   PubMed Web of Science ®Google Scholar
• Zhou JD, Lin J, Zhang TJ, et al. GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. Cancer Med. 2017;6(1):267–274. doi:10.1002/cam4.984.
   PubMed Web of Science ®Google Scholar
• Falconi G, Fabiani E, Piciocchi A, et al. Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia. 2019;33(3):785–790. doi:10.1038/s41375-018-0284-9.
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87. doi:10.1038/leu.2013.269.
   PubMed Web of Science ®Google Scholar
• Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012;30(27):3376–3382. doi:10.1200/JCO.2011.40.7379.
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:10.1186/1745-6215-8-16.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised International prognostic Scoring System for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489.
   PubMed Web of Science ®Google Scholar
• Cedena MT, Rapado I, Santos-Lozano A, et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. 2018;9(56):30936. doi:10.18632/oncotarget.25856.
   PubMedGoogle Scholar
• Cabezón M, Bargay J, Xicoy B, et al. Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine. Oncotarget. 2018;9(27):19342–19355. doi:10.18632/oncotarget.25046.
   PubMedGoogle Scholar
• Du M, Zhou F, Jin R, et al. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis. Leuk Res. 2019;80:11–18. doi:10.1016/j.leukres.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Zini G. Diagnostics and prognostication of myelodysplastic syndromes. Ann Lab Med. 2017;37(6):465–474. doi:10.3343/alm.2017.37.6.465.
   PubMed Web of Science ®Google Scholar
• Bartels S, Schipper E, Hasemeier B, et al. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms. Oncotarget. 2016;7(21):30084–30093. doi:10.18632/oncotarget.8310.
   PubMedGoogle Scholar
• Nazha A, Bejar R. Molecular data and the IPSS-R: How Mutational Burden Can Affect prognostication in MDS. Curr Hematol Malig Rep. 2017;12(5):461–467. doi:10.1007/s11899-017-0407-9.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536–547. doi:10.1056/NEJMoa1611604.
   PubMed Web of Science ®Google Scholar